Home  /  JOINT ACTION 3 (Page 6)

This is the pharmaceutical Joint Assessment PTJA07 – on ustekinumab for the treatment of ulcerative colitis (UC). In September 2019, EMA approved the extension of the indication for ustekinumab to include treatment of adult patients with moderately to severely active

We are pleased to announce that the final assessment for OTCA15 “Irreversible electroporation in liver and pancreatic cancer", together with the input from external experts and manufacturers, are now available for access. Irreversible electroporation (IRE) is a nonthermal ablative method based on

This is the assessment of the relative effectiveness of  ‘Sotagliflozin indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed

We are pleased to announce publication of the collaborative assessment OTCA14 “Robot-assisted surgery for thoracic and visceral surgery”. This is the assessment of the relative effectiveness and safety of robot-assisted surgery for 13 different procedures within the thoracic and visceral surgery

EUnetHTA recently started a new Joint Assessment on a medicinal product for secondary progressive MS. To find out about participation, please read more here. Input submissions will be received through till EOB, April 28th.